though
primarili
synthes
treat
malaria
antimalari
extens
accept
approv
treat
cutan
lupu
interestingli
recent
evid
also
shown
medic
lower
lipid
level
system
lupu
erythematosu
le
play
cardioprotect
role
addit
lower
rate
thrombosi
payn
credit
first
prescrib
antimalari
quinin
treat
patient
lupu
quinin
natur
alkaloid
isol
south
american
cinchona
bark
tree
subsequ
synthet
antimalari
produc
quinacrin
atabrin
mepacrin
chinacrin
acridin
compound
first
antimalari
synthes
quinacrin
replac
quinin
antimalari
compound
world
war
ii
million
american
servicemen
took
quinacrin
year
well
page
effect
treat
cutan
lupu
patient
resist
treatment
quinin
deriv
quinin
chloroquin
hydroxychloroquin
becam
drug
manag
skin
lupu
found
effect
toler
side
effect
lupu
patient
sinc
antimalari
shown
effect
treat
varieti
skin
condit
chloroquin
quinolin
see
fig
isoquinolin
nucleu
doubl
structur
chlorid
atom
posit
alkyl
side
chain
site
chiral
molecul
l
form
clinic
relev
chiral
isoform
remain
subject
debat
drug
manufactur
diphosph
aralen
phosphat
resochin
oral
administr
hydrochlorid
intramuscular
inject
therapi
coma
approxim
diphosph
repres
base
water
solubl
readili
absorb
gastrointestin
tract
pharmacokinet
drug
review
krishna
white
ducharm
oral
administr
peak
plasma
concentr
reach
within
hour
approxim
drug
plasma
bound
protein
dose
mg
daili
lead
stabl
plasma
concentr
ngml
drug
deposit
tissu
time
plasma
concentr
found
liver
spleen
kidney
lung
signific
accumul
drug
also
occur
leukocyt
highest
concentr
drug
found
cell
retina
skin
result
widespread
tissu
deposit
larg
volum
distribut
lkg
chloroquin
undergo
hepat
biotransform
two
activ
metabolit
desethylchloroquin
bisdesethylchloroquin
via
cytochrom
enzym
renal
clearanc
account
half
total
system
clearanc
increas
acidif
urin
pharmacokinet
complex
plasma
level
determin
rate
distribut
rather
rate
elimin
drug
discontinu
daili
dosag
week
plasma
initi
day
gradual
increas
day
week
termin
day
chloroquin
remain
skin
month
cessat
therapi
time
drug
longer
detect
plasma
hydroxychloroquin
differ
chloroquin
presenc
hydroxyl
group
end
side
chain
substitu
fig
avail
oral
administr
hydroxychloroquin
sulfat
plaquenil
mg
contain
mg
base
chiral
form
hydroxychloroquin
similar
pharmacokinet
chloroquin
rapid
gastrointestin
absorpt
larg
volum
distribut
renal
elimin
hydroxychloroquin
cytochrom
enzym
cyp
whether
genotyp
differ
enzym
affect
efficaci
toxic
hydroxychloroquin
still
unknown
maxim
clinic
efficaci
may
take
month
achiev
dose
load
administr
higher
dose
mgday
first
week
shown
acceler
clinic
respons
rheumatoid
arthriti
albeit
increas
incid
gastrointestin
intoler
interestingli
efficaci
drug
correl
drug
blood
concentr
rheumatoid
arthriti
system
le
recent
studi
whole
blood
drug
concentr
measur
unselect
system
lupu
patient
receiv
mg
hydroxychloroquin
least
month
larg
variabl
whole
blood
drug
concentr
note
possibl
due
poor
complianc
yet
unknown
interindividu
pharmacokinet
paramet
mean
whole
blood
concentr
patient
inact
diseas
ngml
significantli
higher
patient
activ
diseas
ngml
low
level
blood
hydroxychloroquin
predictor
exacerb
lead
author
propos
individu
dose
schedul
maintain
whole
drug
concentr
ngml
similar
studi
avail
chloroquin
state
base
therapeut
respons
rheumatoid
arthriti
hydroxychloroquin
approxim
effect
chloroquin
half
toxic
chloroquin
hydroxychloroquin
readili
cross
placenta
hydroxychloroquin
blood
level
fetu
similar
mother
excret
small
amount
breast
milk
quinacrin
extra
benzin
ring
thu
acridin
nucleu
compar
chloroquin
fig
alkyl
side
chain
ident
pharmacokinet
drug
similar
skin
deposit
readili
visibl
yellow
cast
importantli
quinacrin
thu
advers
reaction
one
drug
group
preclud
use
quinacrin
commonli
use
irrit
voluntari
femal
nonsurg
steril
india
due
abil
produc
tubal
occlus
intrauterin
instil
also
use
vesic
pleurodesi
treatment
recurr
pneumothorax
malign
pleural
effus
cell
monocyt
macrophag
dendrit
cell
present
exogen
antigen
origin
cell
class
ii
mhc
molecul
foreign
antigen
digest
within
lysosom
cellular
compart
load
onto
peptid
groov
class
ii
mhc
molecul
chloroquin
interfer
digest
antigen
subsequ
present
antigen
cell
chloroquin
also
prevent
dissoci
invari
chain
class
ii
mhc
molecul
dissoci
must
occur
peptid
load
proceed
thu
chloroquin
interfer
class
ii
mhc
antigen
peptid
load
thought
rel
low
affin
class
ii
mhc
molecul
propos
process
might
preferenti
diminish
respons
self
wherea
lysosomotrop
agent
chloroquin
known
interfer
class
ii
antigen
present
recent
shown
increas
respons
solubl
antigen
singl
dose
chloroquin
day
prior
hepat
b
vaccin
booster
dose
immun
increas
respons
vaccin
shown
interfer
solubl
antigen
degrad
lysosom
increas
export
cytosol
solubl
antigen
could
access
pathway
lead
load
class
mhc
molecul
present
cell
dichotom
effect
inhibit
stimul
promot
stimul
still
need
demonstr
chronic
antimalari
use
may
explain
part
pauciti
opportunist
infect
antimalari
therapi
vitro
studi
shown
chloroquin
hydroxychloroquin
decreas
product
peripher
blood
lymphocyt
inhibit
whole
blood
also
note
although
inhibit
mediat
cytokin
describ
major
cellular
target
appear
macrophag
monocyt
whose
product
readili
inhibit
monotherapi
sle
patient
chloroquin
result
decreas
serum
level
suggest
inhibit
product
mainli
affect
monocyt
may
independ
lysosomotrop
action
drug
relat
nuclear
effect
chloroquin
shown
interfer
phosphoryl
extracellular
kinas
erk
kinas
proteinerk
kinas
mek
thu
inhibit
product
howev
mani
assay
conduct
use
concentr
higher
attain
vivo
may
also
result
mammalian
cell
growth
inhibit
potent
effect
antimalari
recent
note
inhibit
stimul
receptor
tlr
famili
receptor
tlr
cellular
receptor
microbi
product
induc
inflammatori
respons
activ
innat
immun
system
nanomolar
rather
micromolar
concentr
chloroquin
shown
potent
prevent
bacteri
product
human
peripher
blood
mononuclear
cell
effect
known
result
inhibit
signal
found
within
endosom
compart
cell
suscept
inhibit
lysosomotrop
agent
recent
mous
model
rheumatoid
factor
product
b
cell
could
induc
immun
complex
effect
requir
signal
could
inhibit
chloroquin
sle
dna
shown
activ
b
cell
via
sequenti
engag
antigen
receptor
bcr
likewis
signal
promot
activ
autoreact
b
cell
rna
autoantigen
sle
furthermor
necrot
synovi
cell
ra
patient
induc
cytokin
chemokin
product
synovi
fibroblast
mechan
also
stimul
dendrit
cell
produc
inflammatori
cytokin
signal
event
inhibit
low
therapeut
relev
concentr
antimalari
taken
togeth
observ
suggest
chloroquin
hydroxychloroquin
potent
effect
tlr
signal
may
explain
efficaci
treatment
sle
ra
possibl
inflammatori
diseas
effect
primarili
cell
initi
immun
reaction
may
account
delay
onset
action
clinic
previous
activ
cell
perhap
b
cell
less
readili
inhibit
antimalari
act
prostaglandin
antagonist
secondari
inhibit
phospholipas
antimalari
affect
membran
traffic
impair
receptor
recycl
may
alter
inflammatori
cell
respons
mitogen
stimuli
lysosom
effect
may
also
underli
observ
decreas
cell
mediat
cytotox
mediat
lysi
note
patient
antimalari
quinacrin
chloroquin
shown
affect
matrix
metalloprotein
product
leukocyt
increas
nitric
oxid
synthas
activ
note
endotheli
cell
follow
exposur
chloroquin
vitro
whole
anim
model
result
increas
vasopressin
releas
increas
glomerular
filtrat
rate
antimalari
absorb
uv
light
block
cutan
reaction
induc
uv
light
given
topic
intraderm
topic
chloroquin
protect
erythema
immedi
pigment
darken
suggest
uv
absorpt
may
even
major
oper
mechan
topic
applic
quinacrin
note
increas
toler
lupu
patient
light
year
ago
increas
mean
uvb
erythema
dose
med
recent
confirm
lupu
patient
follow
month
chloroquin
therapi
may
result
either
photoprotect
action
drug
antimalari
also
shown
enhanc
protect
earli
limb
uv
respons
inhibit
erk
activ
chloroquin
shown
sensit
hela
cell
apoptosi
likewis
hydroxychloroquin
potenti
apoptosi
synoviocyt
may
explain
increas
sensit
apoptosi
demonstr
lymphocyt
vitro
exposur
hydroxychloroquin
qualiti
demonstr
blockad
abc
drug
transport
made
drug
candid
antineoplast
agent
antimicrobi
effect
upon
hiv
sar
coronaviru
influenza
note
relat
part
interfer
protein
glycosyl
antimalari
also
anticoagul
hypoglycem
effect
chloroquin
inhibit
platelet
aggreg
adhes
clinic
relev
manner
hydroxychloroquin
use
associ
decreas
serum
cholesterol
triglycerid
ldl
level
antimalari
also
decreas
insulin
degrad
thu
improv
glucos
toler
lupu
skin
condit
encompass
acut
cutan
le
subacut
cutan
le
chronic
cutan
le
studi
hydroxychloroquin
discoid
le
establish
efficaci
placebo
month
year
treatment
crossov
hydroxychloroquin
efficaci
placebo
month
similar
result
achiev
larg
open
clinic
studi
patient
chronic
cutan
le
subacut
cutan
le
therapi
also
improv
fatigu
arthralgia
myalgia
seros
mucou
membran
ulcer
sle
patient
antimalari
shown
effect
treat
skin
diseas
oral
mucos
ulcer
calcinosi
cuti
calcifi
lupu
pannicul
photosensit
addit
number
shown
reduc
sle
patient
take
hydroxychloroquin
compar
placebo
hydroxychloroquin
protect
effect
surviv
patient
sle
verruc
hypertroph
plaqu
respond
less
effect
antimalari
therapi
typic
patient
cutan
manifest
start
hydroxychloroquin
mgday
averag
size
adult
maximum
dosag
given
mgkg
lean
bodyweightday
common
formula
calcul
lean
bodi
weight
includ
method
jame
lean
bodi
weight
men
weight
kg
height
lean
bodi
weight
women
weight
kg
height
trial
hydroxychloroquin
improv
seen
quinacrin
ad
initi
dosag
mgday
two
studi
indic
combin
antimalari
use
may
benefit
skin
diseas
interestingli
addit
quinacrin
therapi
patient
stabl
system
lupu
hydroxychloroquin
prednison
shown
decreas
system
activ
score
togeth
lower
serum
level
b
lymphocyt
activ
factor
bli
anticardiolipin
antibodi
titer
antimalari
combin
treatment
clinic
effect
achiev
hydroxychloroquin
dosag
may
lower
mgday
month
well
quinacrin
dosag
may
lower
reduc
side
effect
altern
chloroquin
mg
daili
maximum
dosag
mgkg
lean
bodyweightday
may
use
case
respond
hydroxychloroquin
also
combin
quinacrin
combin
hydroxychloroquin
chloroquin
avoid
due
risk
retin
toxic
clinic
improv
cutan
le
seen
sever
week
later
use
antimalari
therefor
month
consid
standard
time
frame
chang
anoth
therapi
intralesion
topic
corticosteroid
effect
provid
quick
improv
patient
porphyria
cutanea
tarda
pct
usual
treatment
involv
phlebotomi
howev
use
antimalari
therapi
may
indic
patient
contraind
failur
receiv
phlebotomi
use
antimalari
children
may
prefer
use
phlebotomi
latter
traumat
patient
discoveri
use
antimalari
therapi
pct
made
patient
given
hydroxychloroquin
chloroquin
result
acut
exacerb
hepat
diseas
howev
recoveri
acut
exacerb
result
clinic
remiss
use
antimalari
may
initi
either
low
dosag
prevent
acut
exacerb
given
intent
high
dosag
hospit
patient
well
antimalari
therapi
combin
patient
pretreat
one
four
phlebotomi
therapi
start
either
choroquin
mg
twice
weekli
hydroxychloroquin
mg
two
time
weekli
dosag
increas
depend
clinic
respons
patient
recommend
author
given
test
dose
mg
chloroquin
examin
liver
function
test
initi
use
hydroxychloroquin
consist
mg
three
time
daili
day
report
use
patient
increas
serum
transaminas
note
patient
receiv
regimen
advis
hospit
though
accept
first
line
treatment
polymorph
light
erupt
pmle
antimalari
therapi
shown
effect
patient
two
control
efficaci
trial
use
hydroxychloroquin
chloroquin
demonstr
increas
sun
toler
moder
clinic
improv
seen
statist
signific
skin
rash
reduct
treatment
regimen
ineffect
sun
avoid
failur
contraind
receiv
prophylact
uvb
puva
phototherapi
exist
intermitt
hydroxychloroquin
mg
daili
prior
increas
sun
exposur
tri
muscl
involv
dermatomyos
tend
respond
well
use
system
corticosteroid
immunosuppress
agent
howev
cutan
lesion
still
persist
author
articl
found
use
hydroxychloroquin
mgdaili
improv
cutan
manifest
dermatomyos
open
studi
contain
seven
patient
cutan
lesion
dermatomyos
fail
respond
therapi
improv
seen
patient
use
hydroxychloroquin
three
show
complet
resolut
anoth
retrospect
studi
look
patient
dermatomyos
one
lab
criterion
muscl
involv
muscl
weak
five
patient
show
complet
improv
four
show
partial
improv
receiv
hydroxychloroquin
addit
two
patient
taken
hydroxychloroquin
cutan
rash
flare
clear
receiv
treatment
hydroxychloroquin
also
shown
effect
childhood
dermatomyos
shown
studi
consist
nine
patient
incomplet
respons
corticosteroid
flare
corticosteroid
lower
hydroxychloroquin
patient
show
signific
improv
cutan
symptom
month
also
reduct
proxim
abdomin
muscl
weak
hydroxychloroquin
recommend
treatment
dermatomyos
patient
cutan
lesion
respond
steroid
patient
cutan
involv
without
muscl
involv
term
amyopath
dermatomyos
recent
use
combin
antimalari
treatment
addit
quinacrin
quinolon
shown
benefit
patient
respond
singl
quinolon
antimalari
alon
promot
antimalari
solar
urticaria
base
two
anecdot
report
demonstr
effect
therapi
therefor
trial
compar
efficaci
antimalari
antimalari
therapi
may
tri
antihistamin
phototherapi
photochemotherapi
plasmapheresi
ineffect
british
tuberculosi
associ
evalu
efficaci
chloroquin
therapi
given
month
patient
sarcoidosi
random
clinic
trial
patient
show
signific
improv
patient
month
month
two
group
show
differ
demonstr
therapi
suppress
mechan
anoth
studi
patient
cutan
sarcoidosi
treat
hydroxychloroquin
mg
daili
four
week
treatment
result
improv
skin
lesion
cutan
sarcoidosi
antimalari
thu
effect
altern
corticosteroid
therapi
granuloma
annular
known
resist
mani
form
treatment
sever
case
report
publish
show
effect
treatment
granuloma
annular
use
antimalari
open
trial
carri
children
gener
granuloma
annular
result
complet
clearanc
lesion
week
therapi
also
recent
publish
two
children
gener
granuloma
annular
clear
receiv
antimalari
therefor
antimalari
may
consid
effect
treatment
choic
topic
therapi
fail
granuloma
annular
clinic
histopatholog
resembl
oral
lesion
lichen
planu
le
led
determin
antimalari
therapi
effect
oral
lichen
planu
ten
patient
enrol
open
trial
receiv
hydroxychloroquin
mg
daili
month
excel
respons
seen
nine
patient
effect
earli
month
therapi
discontinu
four
patient
recurr
seen
month
wherea
six
patient
mainten
treatment
observ
woman
lichen
planu
lower
lip
treat
success
chloroquin
although
first
line
therapi
oral
lichen
planu
intralesion
topic
corticosteroid
antimalari
therapi
consid
resist
case
studi
lupu
pannicul
patient
treat
antimalari
therapi
patient
clinic
improv
within
month
demonstr
effect
antimalari
therapi
patient
well
sever
case
report
shown
complet
resolut
lupu
pannicul
lesion
antimalari
treatment
although
one
case
le
profundu
show
clearanc
lesion
use
chloroquin
improv
dapson
two
case
pannicul
shown
treat
success
one
woman
oral
chloroquin
mg
daili
boy
treat
hydroxychloroquin
mgkgday
allow
reduct
system
prednison
therapi
use
hydroxychloroquin
report
effect
chronic
erythema
nodosum
recent
use
antimalari
report
treat
lipoatroph
pannicul
convinc
evid
demonstr
antimalari
effect
lupu
pannicul
form
pannicul
studi
need
perform
prove
effect
chronic
ulcer
stomat
tend
resist
use
local
system
corticosteroid
howev
antimalari
shown
effect
consid
agent
rare
condit
antimalari
shown
effect
case
epidermolysi
bullosa
atop
dermat
eosinophil
fasciiti
scleroderma
urticari
vascul
reticular
erythemat
mucinosi
absolut
contraind
use
antimalari
hypersensit
prescrib
patient
histori
retinopathi
contraind
caution
use
patient
document
neuromuscular
disord
myasthenia
gravi
well
patient
psychot
disord
patient
defici
care
monitor
although
hemolysi
occur
recommend
dosag
antimalari
cutan
diseas
discuss
previou
discuss
patient
porphyria
cutanea
tarda
antimalari
known
caus
acut
hepat
defici
porphyria
cutanea
tarda
rare
routin
test
condit
recommend
current
evid
use
pregnanc
lactat
discuss
succeed
discuss
evid
transplacent
passag
hydroxychloroquin
recent
shown
level
hydroxychloroquin
exposur
fetu
similar
matern
level
howev
subsequ
clinic
studi
carri
author
conclud
hydroxychloroquin
overal
benefici
treatment
pregnant
lupu
patient
compar
control
random
control
trial
pregnant
lupu
patient
compar
hydroxychloroquin
placebo
treatment
assess
effect
safeti
hydroxychloroquin
group
consist
eight
patient
system
lupu
two
discoid
lupu
wherea
placebo
group
nine
one
patient
system
lupu
discoid
lupu
respect
hydroxychloroquin
group
higher
deliveri
age
apgar
score
congenit
abnorm
auditori
defect
retin
toxic
note
three
year
follow
seen
given
hydroxychloroquin
contrast
three
patient
flare
placebo
group
studi
conclud
hydroxychloroquin
start
pregnanc
treatment
lupu
anoth
prospect
studi
evalu
lupu
pregnanc
patient
receiv
hydroxychloroquin
observ
similar
result
patient
examin
receiv
hydroxychloroquin
quinacrin
first
trimest
pregnanc
found
congenit
abnorm
eye
hear
defect
note
deliveri
examin
howev
author
studi
conclud
effect
fetal
exposur
comment
british
studi
retrospect
review
patient
receiv
hydroxychloroquin
mean
durat
pregnanc
week
control
two
differ
group
differ
obstetr
outcom
congenit
abnorm
seen
hydroxychloroquin
use
author
also
comment
differ
seen
diseas
activ
well
group
antimalari
use
pregnanc
advis
hydroxychloroquin
util
antimalari
sever
reason
lower
toxic
bind
less
avidli
tissu
unlik
chloroquin
associ
caus
retin
toxic
fetu
ii
treatment
antiphospholipid
antibodi
syndrom
shown
hydroxychloroquin
iii
hydroxychloroquin
found
decreas
quantiti
breast
milk
compar
chloroquin
evid
usag
antimalari
lactat
well
establish
recent
infant
expos
hydroxychloroquin
given
mother
pregnanc
lactat
observ
normal
visual
function
neurodevelop
outcom
earli
infanc
mechan
action
antimalari
induc
psoriasi
current
believ
twofold
antimalari
block
uv
radiat
ii
inhibit
transglutaminas
antimalari
compris
epiderm
barrier
function
specul
antimalari
may
also
indirectli
enhanc
activ
increas
shuttl
solubl
antigen
class
mhc
molecul
antimalari
use
extens
patient
psoriasi
effect
reduc
inflam
joint
psoriat
arthriti
therapi
note
patient
tend
flare
psoriasi
howev
subsequ
studi
shown
incid
psoriasi
antimalari
substanti
vari
militari
patient
receiv
malaria
prophylaxi
weekli
dose
mg
chloroquin
mg
primaquin
studi
twenti
patient
mild
moder
worsen
psoriasi
three
patient
becam
resist
topic
therapi
one
studi
conclud
hydroxychloroquin
associ
psoriasi
patient
treat
psoriat
arthriti
howev
pustular
psoriasi
occasion
report
occur
similar
set
one
review
indic
quinacrin
associ
higher
frequenc
exfoli
erythroderma
chloroquin
higher
chanc
caus
signific
psoriasi
hydroxychloroquin
shown
lower
rate
reaction
author
claim
antimalari
induc
psoriasi
de
novo
trigger
exist
diseas
systemat
review
discrep
report
recent
conclud
evid
insuffici
either
refut
support
role
antimalari
exacerb
psoriasi
antimalari
shown
caus
advers
ocular
effect
revers
patient
taken
antimalari
except
retinopathi
chloroquin
patient
occasion
experi
blurri
vision
diplopia
therapi
initi
symptom
usual
resolv
time
dosag
decreas
effect
observ
hydroxychloroquin
although
corneal
deposit
usual
asymptomat
patient
experi
see
halo
around
light
find
corneal
deposit
examin
contraind
continu
treatment
deposit
relat
dosag
usual
appear
month
therapi
initi
revers
resolut
occur
usual
month
therapi
discontinu
easterbrook
estim
approxim
patient
chloroquin
mg
daili
develop
corneal
deposit
contrast
patient
receiv
hydroxychloroquin
mg
daili
corneal
deposit
observ
seriou
ocular
toxic
antimalari
retinopathi
absolut
contradict
continu
therapi
retinopathi
earli
stage
call
premaculopathi
revers
advers
effect
character
chang
visual
field
fundoscop
examin
associ
vision
loss
progress
zone
depigment
surround
pigment
part
macula
encircl
area
pigment
result
bull
eye
appear
retin
toxic
seen
patient
receiv
high
standard
dosag
antimalari
regimen
recent
studi
shown
toxic
limit
lower
effect
dosag
patient
monitor
studi
nine
patient
receiv
less
mgkgday
hydroxychloroquin
total
cumul
dose
greater
g
g
individu
acquir
retin
toxic
second
studi
largest
retrospect
studi
hydroxychloroquin
retin
toxic
contain
patient
follow
year
also
observ
toxic
dosag
rang
mackenzi
follow
patient
rheumatoid
arthriti
year
determin
retinopathi
associ
cumul
daili
dosag
regimen
patient
receiv
greater
kg
chloroquin
hydroxychloroquin
observ
find
mean
daili
dosag
mgkgday
chloroquin
mgkgday
hydroxychloroquin
progress
retinopathi
ii
mgkgday
chloroquin
mgkgday
hydroxychloroquin
develop
retinopathi
therefor
mackenzi
conclud
studi
recommend
safe
dosag
chloroquin
less
mgkgday
hydroxychloroquin
less
mgkgday
prevent
retinopathi
review
literatur
shown
chloroquin
mgday
oculotox
hydroxychloroquin
mgday
wherea
quinacrin
rel
lack
retin
toxic
two
question
case
retinotox
report
quinacin
use
thu
specialist
recommend
routin
ophthalmolog
patient
drug
american
academi
ophthalmolog
aao
screen
guidelin
recommend
patient
place
hydroxychloroquin
mgkdaday
chloroquin
mgkgday
base
guidelin
patient
divid
two
categori
patient
receiv
lower
dosag
use
drug
year
patient
receiv
higher
dosag
risk
factor
high
bodi
fat
level
concomit
kidney
liver
diseas
concomit
retin
diseas
year
age
patient
baselin
ophthalmolog
examin
within
year
start
medic
includ
examin
retina
dilat
pupil
test
central
visual
field
sensit
either
grid
chart
amsler
grid
autom
field
tester
humphrey
test
patient
categori
test
requir
year
initi
baselin
examin
normal
accord
aao
guidelin
wherea
patient
categori
examin
annual
toxic
appear
develop
elabor
test
recommend
multifoc
electroretinographi
antimalari
report
stimul
cerebr
cortex
particular
quinacrin
lesser
effect
chloroquin
frequent
manifest
report
patient
includ
nightmar
headach
side
effect
includ
irrit
nervous
psychosi
seizur
hyperexcit
musculoskelet
symptom
report
literatur
occur
usag
antimalari
resolv
cessat
therapi
chloroquin
occasion
caus
myalgia
fatigu
onset
treatment
well
neuromyopathi
report
sever
patient
chloroquin
sle
patient
treat
hydroxychloroquin
two
patient
develop
proxim
myopathi
posit
electromyographi
use
antimalari
patient
defici
report
caus
hemolysi
agranulocytosi
aplast
anemia
uncommonli
observ
patient
receiv
chloroquin
quinacrin
although
rare
antimalari
caus
sever
leukopenia
patient
hematolog
advers
effect
caus
antimalari
revers
cessat
therapi
risk
aplast
anemia
report
patient
receiv
quinacrin
requir
bone
marrow
transplant
risk
estim
patient
normal
monitor
complet
blood
count
cbc
baselin
follow
cbc
monthli
month
everi
month
cardiac
side
effect
prescrib
antimalari
treatment
cutan
lesion
rare
howev
recent
case
report
woman
treat
antimalari
year
discoid
le
subsequ
develop
conduct
disturb
congest
heart
failur
chf
cardiotox
commonli
seen
patient
treat
system
le
usual
antimalari
known
caus
conduct
disturb
chf
chloroquin
less
frequent
hydroxychloroquin
manifest
gastrointestin
symptom
occur
descend
order
quinacrin
chloroquin
follow
hydroxychloroquin
common
symptom
includ
nausea
vomit
diarrhea
patient
present
addit
symptom
anorexia
heartburn
abdomin
distens
elev
transaminas
manifest
transient
resolv
time
decreas
dosag
liver
function
test
usual
taken
baselin
measur
monthli
month
follow
monitor
everi
month
black
pigment
observ
patient
receiv
antimalari
therapi
darker
pigment
associ
quinacrin
compar
hydroxychloroquin
chloroquin
pigment
chang
typic
seen
face
hard
palat
forearm
shin
melanin
granul
hemosiderin
deposit
observ
within
dermi
biopsi
addit
root
hair
becom
bleach
success
streak
nailb
may
develop
transvers
band
cutan
manifest
resolv
sever
month
cessat
therapi
pruritu
cutan
erupt
occur
patient
take
antimalari
cutan
manifest
report
includ
morbilliform
exfoli
dermat
urticaria
eczemat
alopecia
photosensit
erythroderma
erythema
annular
centrifugum
recent
report
suggest
cutan
advers
reaction
antimalari
may
common
patient
dermatomyos
note
roughli
patient
treat
one
center
patient
lupu
histor
reaction
rate
roughli
patient
took
quinacrin
world
war
ii
develop
lichenoid
erupt
rate
soldier
mg
daili
soldier
take
mg
daili
therapi
three
patient
observ
develop
squamou
cell
carcinoma
howev
two
patient
also
radiat
therapi
medic
continu
month
year
despit
onset
erupt
propos
lichenoid
tissu
reaction
may
preced
quinacrin
bone
marrow
toxic
antimalari
exhibit
sever
import
drug
interact
highlight
section
combin
hydroxychloroquin
treatment
chloroquin
given
due
potenti
retinotox
level
penicillamin
digoxin
may
increas
hydroxychloroquin
chloroquin
usag
metoprolol
level
shown
increas
usag
hydroxychloroquin
chloroquin
reduc
bioavail
ampicillin
increas
cyclosporin
level
kaolin
may
decreas
absorpt
chloroquin
therefor
intak
medic
within
hour
chloroquin
therapi
activ
possibl
chloroquin
seen
amiodaron
chlorpromazin
therefor
caution
use
prescrib
medic
concurr
cimetidin
tend
impair
elimin
chloroquin
simultan
usag
chloroquin
hepatotox
drug
increas
risk
hepatotox
use
mefloquin
seizur
antimalari
interfer
neuromuscular
transmiss
therefor
use
patient
disrupt
neuromuscular
transmiss
via
predispos
condit
secondari
medic
smoke
report
inhibit
enzym
system
decreas
efficaci
antimalari
therapi
furthermor
nicotin
may
inhibit
lysosom
uptak
antimalari
recent
studi
show
differ
effect
smoker
howev
lower
number
patient
studi
could
account
fail
detect
differ
antimalari
use
dermatologist
year
princip
manag
cutan
le
compar
immunomodulatori
agent
antimalari
favor
safeti
profil
major
mode
action
appear
inhibit
endosom
tlr
signal
result
reduc
activ
mode
action
obviou
relev
drug
efficaci
treatment
le
mode
action
may
also
explain
benefici
effect
drug
dermatos
lichen
planu
granulomat
dermatos
sarcoidosi
granuloma
annular
new
understand
toxic
mode
action
drug
may
suggest
new
applic
modifi
treatment
regimen
